The impact of XPC gene single nucleotide polymorphism rs2228001 on head and neck cancer patients’ response to radiotherapy treatment
Abstract
Background: Head and neck squamous carcinoma (HNSC) is the sixth most common neoplasm, with a 40–50% overall survival rate. HNSC standard treatment depends on tumor size, metastasis or human papillomavirus (HPV) status including surgery, chemotherapy, and radiotherapy. The last two may lead to defects in the tumor microenvironment and cancer cell biology as disorders in DNA damage repair systems.
Here, we evaluate the correlation between single nucleotide polymorphism (SNP) rs2228001 in the XPC gene with the early and late adverse effects of radiotherapy, determine the distribution of the SNP and post-treatment follow-up in HNSC patients.
Materials and methods: Head and neck cancer tissues and clinical data were obtained from 79 patients. The SNP of the XPC gene (rs2228001) was evaluated with polymerase chain reaction — restriction fragment length polymorphism (PCR-RFLP). The chi-square test was used to determine the correlation between mutation and adverse effects occurrence.
Results/Conclusion: Single nucleotide polymorphism rs2228001 in the XPC gene is correlated with the early adverse effect of skin reaction and the late adverse effect of elevated C-reactive protein (CRP) levels in the HNSC patients.
Keywords: head and neck cancerXPCdamage repair systemsradiotherapyadverse effects
References
- Barsouk A, Aluru JS, Rawla P, et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023; 11(2).
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Bray F, Colombet M, Mery L, Piñeros M. et al. (ed). Cancer Incidence in Five Continents. Vol XI. IARC Publications 2021.
- Machiels JP, René Leemans C, Golusinski W, et al. EHNS Executive Board. Electronic address: secretariat@ehns.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESTRO Executive Board. Electronic address: info@estro.org. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1462–1475.
- Allgar VL, Oliver SE, Chen H, et al. Time intervals from first symptom to diagnosis for head and neck cancers: An analysis of linked patient reports and medical records from the UK. Cancer Epidemiol. 2019; 59: 37–45.
- Brook I. Early side effects of radiation treatment for head and neck cancer. Cancer Radiother. 2021; 25(5): 507–513.
- Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J. 2020; 38(2): 84–92.
- Monjazeb AM, Schalper KA, Villarroel-Espindola F, et al. Effects of Radiation on the Tumor Microenvironment. Semin Radiat Oncol. 2020; 30(2): 145–157.
- Barker HE, Paget JTE, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15(7): 409–425.
- Wu C, Xu C, Wang G, et al. Noninvasive circulating tumor cell and urine cellular (rs2228001, A2815C) and (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers. Transl Cancer Res. 2019; 8(8): 2803–2812.
- Das S, Naher L, Aka TD, et al. The rs11615, rs2276466, rs2228000 and rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population. Heliyon. 2021; 7(1): e05919.
- Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol. 2006; 37(5-7): 225–238.
- Wang Y, Spitz MR, Lee JJ, et al. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res. 2007; 13(12): 3753–3758.
- He BS, Xu T, Pan YQ, et al. Nucleotide excision repair pathway gene polymorphisms are linked to breast cancer risk in a Chinese population. Oncotarget. 2016; 7(51): 84872–84882.
- Li B, Yabluchanskiy A, Tarantini S, et al. Measurements of cerebral microvascular blood flow, oxygenation, and morphology in a mouse model of whole-brain irradiation-induced cognitive impairment by two-photon microscopy and optical coherence tomography: evidence for microvascular injury in the cerebral white matter. Geroscience. 2023; 45(3): 1491–1510.
- Mohamed AE, Hassouna AH, Mosalum HS, et al. The outcome of early-stage glottic carcinoma patients treated with radiotherapy: Egyptian National Cancer Institute (NCI-Egypt) experience. Rep Pract Oncol Radiother. 2023; 28(4): 496–505.
- Marteijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014; 15(7): 465–481.
- Rajabi-Moghaddam M, Abbaszadeh H. Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review. Rep Pract Oncol Radiother. 2022; 27(6): 1058–1076.
- Kozłowska-Masłoń J, Guglas K, Kolenda T, et al. miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology. Rep Pract Oncol Radiother. 2023; 28(5): 681–697.
- Duan M, Ulibarri J, Liu KeJ, et al. Role of Nucleotide Excision Repair in Cisplatin Resistance. Int J Mol Sci. 2020; 21(23).
- Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, et al. XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. Front Pharmacol. 2018; 9: 1197.
- Zhang Yi, Cao J, Meng Y, et al. Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. Oncol Lett. 2018; 15(5): 6336–6344.
- Teng X, Fan XF, Li Qi, et al. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Oncol Rep. 2019; 41(3): 1875–1882.
- Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001; 1(1): 22–33.